Rani Therapeutics Holdings Inc expected to post a loss of 25 cents a share - Earnings Preview

Rani Therapeutics Holdings

28/03/2025 20:48

Rani Therapeutics Holdings Inc RANI.OQ RANI.O is expected to show no change in quarterly revenue when it reports  results on March 31 for the period ending December 31 2024

​LSEG's mean analyst estimate for Rani Therapeutics Holdings Inc is for a loss of 25 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Rani Therapeutics Holdings Inc is $11.50​, above​ its last closing price of $1.34. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.20
-0.26
-0.24
Beat
7.1
Jun. 30 2024
-0.33
-0.32
-0.26
Beat
17.6
Mar. 31 2024
-0.21
-0.20
-0.29
Missed
-42.6​
Dec. 31 2023
-0.32
-0.31
-0.27
Beat
13.4
​​Sep. 30 2023
-0.38
-0.37
-0.36
Beat
1.6
Jun. 30 2023
-0.35
-0.40
-0.37
Beat
8.5​
Mar. 31 2023
-0.39
-0.41
-0.33
Beat
20.2
Dec. 31 2022
-0.36
-0.35
-0.35
Met
-0.6

This summary was machine generated March 28 at 20:48 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)